The AQ312 program is based on the drug candidate AQ312, which targets a core receptor known as AhR for the treatment of inflammatory bowel diseases.

Modulating the AhR receptor stimulates the body’s innate immune system to boost the quantity of cells in the intestinal lining that have the ability to mitigate inflammation. A drug that reduces inflammation specifically in the colon could potentially alleviate symptoms for patients with ulcerative colitis (UC).